Valeant Pharma (VRX) CFO Buys 24K Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Valeant Pharma (VRX) Director De Schutter Buys 10K Shares
March 16, 2017 5:17 PM EDTValeant Pharma (NYSE: VRX) Director, Richard De Schutter, bought 10,000 shares on 03/15 at $10.80
... MoreValeant Pharma (VRX) Pops 5% After-Hours Following 3M Share Purchase by ValueAct, Holding a 5.2% Stake
March 16, 2017 5:07 PM EDTValeant Pharma (NYSE: VRX) up 5% after-hours following news ValueAct purchased 3mm shares of the company.
ValueAct Buys 3M Valeant Pharma (VRX) Shares
March 16, 2017 4:35 PM EDTValueAct disclosed buying 3 million Valeant Pharma (NYSE: VRX) shares.
Shares were purchased on 03/14 at $10.81-$10.88 and follows Bill Ackman's recent liquidation of his position.
The latest purchase brings ValueAct's stake in Valeant to 17,997,224 shares, or 5.2%.
From ValueAct's related 13D:
The Reporting Persons acquired the securities of the Issuer reported herein based on their belief that the securities were undervalued and represented an attractive investment opportunity.
D. Robert Hale, a Partner of ValueAct Holdings and ValueAct Holdings GP, serves on the board of directors of the... More
